KRONOS BIO
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.
KRONOS BIO
Industry:
Biotechnology Chemical Therapeutics
Founded:
2017-01-01
Address:
San Mateo, California, United States
Country:
United States
Website Url:
http://www.kronosbio.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
278 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Domain Not Resolving Wordpress Plugins
Similar Organizations
1859
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Private Equity Round - Kronos Bio
Vida Ventures
Vida Ventures investment in Private Equity Round - Kronos Bio
Commodore Capital
Commodore Capital investment in Private Equity Round - Kronos Bio
Woodline Partners
Woodline Partners investment in Private Equity Round - Kronos Bio
Nextech Invest
Nextech Invest investment in Private Equity Round - Kronos Bio
Invus
Invus investment in Private Equity Round - Kronos Bio
GV
GV investment in Private Equity Round - Kronos Bio
T. Rowe Price
T. Rowe Price investment in Private Equity Round - Kronos Bio
BlackRock
BlackRock investment in Private Equity Round - Kronos Bio
Surveyor Capital
Surveyor Capital investment in Private Equity Round - Kronos Bio
Key Employee Changes
Official Site Inspections
http://www.kronosbio.com Semrush global rank: 4.57 M Semrush visits lastest month: 2.27 K
- Host name: cloudproxy10069.sucuri.net
- IP address: 192.124.249.69
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Kronos Bio"
Company - Kronos Bio
About Us We are a clinical-stage biopharmaceutical company dedicated to the discovery and development of therapeutics that target the deregulated transcription that causes cancer and autoimmune diseases. Our team finds …See details»
Kronos Bio - Crunchbase Company Profile & Funding
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically …See details»
Kronos Bio, Inc. - AnnualReports.com
Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer. The company is developing the CDK9 inhibitor KB-0742 …See details»
Kronos Bio - LinkedIn
Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases.See details»
People and Science - Kronos Bio
Jan 9, 2023 Eventually we grew beyond our startup space and moved to a larger incubator, and then eventually our own offices on each coast. What sparked this catalyst of events was the onboarding of industry veterans who …See details»
Kronos Bio Implements New Leadership Structure to …
Jan 25, 2024 Company eliminates three executive officer roles and appoints new Executive Leadership teamSAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON ...See details»
Kronos Bio Reports Recent Business Progress and Fourth-Quarter …
Mar 21, 2024 [email protected]. Contact. Headquarters. Kronos Bio, Inc. 1300 So. El Camino Real Suite 400 San Mateo, CA 94402 +1 (650) 781-5200. Research Facility. Kronos …See details»
Kronos Bio Announces Restructuring to Focus Resources on …
Mar 7, 2024 [email protected]. Contact. Headquarters. Kronos Bio, Inc. 1300 So. El Camino Real Suite 400 San Mateo, CA 94402 +1 (650) 781-5200. Research Facility. Kronos …See details»
Kronos Bio Reports Recent Business Progress and Fourth-Quarter …
Dec 31, 2022 [email protected]. Media: Leo Vartorella/David Rosen Argot Partners 212-600-1494 [email protected]. Kronos Bio, Inc. Statements of Operations and …See details»
Kronos Bio Implements New Leadership Structure to Drive Pipeline ...
Jan 25, 2024 I take great pride in having been a key architect in shaping the organization’s trajectory and building its culture.” Kronos Bio has expected cash runway into 2026.See details»
Kronos Bio Announces CEO Transition and Reduction in Force
4 days ago SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics to …See details»
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus …
[email protected]. Investors: Claudia Styslinger Argot Partners 212-600-1902 [email protected]. Media: Sheryl Seapy Real Chemistry 949-903-4750 …See details»
Clinical Trials - Kronos Bio
To learn more about our KB-0742 clinical trial please see below or reach out to us at [email protected] for more information. CDK9 Inhibitor. Phase 1/2 Study of KB …See details»
Kronos Bio Announces Discovery Collaboration with Genentech
Jan 9, 2023 Kronos Bio will receive a $20 million upfront payment and could receive up to an additional $554 million in milestone payments Agreement will leverage...See details»
Kronos Bio, Inc. (KRON) - Yahoo Finance Canada
Find the latest Kronos Bio, Inc. (KRON) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
People and Science - Kronos Bio
Oct 10, 2023 In 2017, Luis transitioned to the biotechnology industry, working for companies in the Boston area focused on hematology and immuno-oncology. In 2021, he joined Kronos Bio, …See details»
Events & Presentations - Kronos Bio
Mar 5, 2024 Kronos Bio, Inc. 1300 So. El Camino Real Suite 400 San Mateo, CA 94402 +1 (650) 781-5200See details»
Science - Kronos Bio
Our Science Deregulated transcription is a hallmark of cancer and autoimmune diseases. Kronos Bio is focused on developing medicines that target deregulated transcription factor activity. In …See details»
Pipeline - Kronos Bio
Nov 13, 2024 Pipeline Kronos Bio is evaluating strategic alternatives per the November 13, 2024 press release TRN Candidate & Indication Discovery IND-enabling Phase 1 Phase 2 Phase 3 …See details»